Efficacy and safety of Mexidol FORTE 250 in sequential therapy of patients with chronic cerebral ischemia

Authors:
N.G. KATAEVA ¹ , T.A. ZAMOSHCHINA ^1,2 , M.V. SVETLIK ^1,2

¹ Federal State Budgetary Educational Institution of Higher Education “Siberian State Medical University” of the Ministry of Health of the Russian Federation, Tomsk, Russia;
² Federal State Autonomous Educational Institution of Higher Education “National Research Tomsk State University”, Tomsk, Russia

Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2020, Vol. 120, No. 11

Abstract:
Objective of the study. To study the efficacy and safety of sequential therapy with Mexidol (intravenous drip injections for 14 days — saturation phase) and Mexidol FORTE 250 (tablets for 60 days — phase of maximization of therapeutic effect) in patients with chronic cerebral ischemia (CCI) against the background of arterial hypertension and atherosclerosis. Material and methods. In the Mexidol therapy group, 27 patients (24 women and 3 men) with CCI stage I-II against the background of a combination of arterial hypertension and atherosclerosis were observed, receiving treatment with Mexidol intravenously by drip (500 mg once a day) for 14 days, followed by oral administration of Mexidol FORTE 250 at a daily dose of 750 mg (1 tablet 3 times a day) for 60 days. The comparison group consisted of 30 patients (22 women and 8 men) with stage I-II CCI, matched for age, risk factor profile, and severity of neurological manifestations. Patients in both groups received background therapy to correct their existing risk factors. Motor activity (Tinetti test), cognitive function (MoCA test), anxiety and depression (Hamilton Depression Rating Scale), and the Clinical Global Impression scale were assessed. Results and conclusion. Inclusion of Mexidol and Mexidol FORTE 250 in standard CCI therapy as sequential long-term therapy is advisable. The obtained results indicate greater clinical efficacy and sufficient safety of the combination therapy. By the end of the study (day 74), patients in the Mexidol therapy group demonstrated a significant improvement in motor activity, cognitive functions, and emotional sphere, as well as a decrease in fatigue and neurological manifestations, compared with the comparison group. Key words: chronic cerebral ischemia, Mexidol, Mexidol FORTE 250.